promise-meso: pembrolizumab vs. standard chemotherapy for mesothelioma
Published 5 years ago • 185 plays • Length 2:59Download video MP4
Download video MP3
Similar videos
-
5:00
promise-meso trial results: pembrolizumab vs chemotherapy for advanced pleural mesothelioma
-
2:36
discussion of the results from the beat-meso trial in pleural mesothelioma
-
1:33
exciting randomized trials for mesothelioma: checkpoint inhibitor monotherapies and vinorelbine
-
0:40
beat-meso: phase iii trial of bevacizumab and chemo ± atezolizumab for advanced pleural mesothelioma
-
2:11
pembrolizumab vs. chemo in first-line mcrc
-
2:58
updates in treating mesothelioma
-
4:54
researcher comment: promise-meso trial fails to meet primary endpoint | sanjay popat
-
4:10
mesothelioma: keytruda® / pembrolizumab chemo receives fda approval
-
22:32
mesotv | open clinical trial: keytruda (pembrolizumab) with or without anetumab ravtansine, ep. 10
-
3:33
immunotherapy for mesothelioma
-
2:12
atomic-meso: pegargiminase in malignant pleural mesothelioma
-
0:25
resectable mesothelioma #2023 #oncology #lungcancer
-
3:15
pembrolizumab demonstrates promise in patients with pretreated metastatic gastric cancer
-
2:06
checkmate-743 study in mesothelioma
-
7:20
mesothelioma: mars2 & mesotrap
-
1:34
the need for rcts in immunotherapy for mesothelioma
-
4:54
background of the keynote-158 trial for pembrolizumab in advanced mesothelioma
-
1:43
mesomics: molecular characterization of malignant pleural mesothelioma
-
2:18
dr. baas on the promise of immuno-oncology in mesothelioma